Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions with or without 40 mM aspartate

ABSTRACT: RNA-seq of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions with or without 40 mM aspartate

PROVIDER: PRJNA1056036 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions with or without 40 mM aspartate

Project description:Iron is an irreplaceable co-factor for metabolism and iron deficiency affects >1 billion people, causing anaemia and impairing immunity. How iron deprivation influences normal cellular function remains poorly characterised. In activated CD8+ T-cells we found that iron scarcity profoundly stalled proliferation and disrupted mitochondrial redox control without influencing cell viability. The TCA cycle was partially redirected to a reductive trajectory, and the repressive H3K27me3 histone mark, usually decreased post-activation, was maintained. Surprisingly, aspartate, which is crucial for proliferation, was increased in stalled iron deficient cells but was not utilised cytosolically, indicating trapping within depolarised mitochondria. Exogenous aspartate increased ATP, suppressed H3K27me3 and markedly rescued clonal expansion. We propose that iron scarcity creates a metabolic bottleneck impairing activation and proliferation of T-cells, and which is bypassed by resupplying biochemical processes with aspartate. These findings reveal mechanistic consequences of iron deficiency and shed light on the response of T-cells to nutritional variation.

2025-03-22 | GSE251963 | GEO

ChIP-seq of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

Project description:ChIP-seq of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

| PRJNA1056035 | ENA

Mtc91 - H3K27me3 ChIPmentation of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

Project description:Mtc91 - H3K27me3 ChIPmentation of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

| PRJNA1238335 | ENA

RNA-seq of naïve and activated murine CD8+ T-cells cultured in high iron (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

Project description:RNA-seq of naïve and activated murine CD8+ T-cells cultured in high iron (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

| PRJNA1056032 | ENA

ChIP-seq of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

2025-03-22 | GSE251964 | GEO

Mtc91 - H3K27me3 ChIPmentation of activated murine CD8+ T-cells cultured in high (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

2025-03-22 | GSE292414 | GEO

RNA-seq of naïve and activated murine CD8+ T-cells cultured in high iron (0.625 mg/mL holotransferrin) or low iron (0.001 mg/mL holotransferrin) conditions

2025-03-22 | GSE251962 | GEO

C. elegans : Control vs. Chlorpyrifos (0.5mg/ml) + Diazinon (1 mg/ml) treatment

Project description:Transcriptional profile of C. elegans comparing control vs. nematodes treated with 0.5 mg/ml of Chlorpyrifos and 1mg/ml of Diazinon (DZN) at 16°C. Toxicant was added to agar and nematode culture on petri dishes for 72h before harvesting.

2010-07-22 | GSE16698 | GEO

CAFFEINE 01 MG/ML Agilent Q TOF

Project description:LC-MS injection of Caffeine 0.1 mg/ml by LC/MS Q TOF

2023-06-08 | MSV000092128 | MassIVE

Effect of Pirfenidone on NSCLC [A549/H1975 0.75 mg/ml Pirf]

Project description:Investigating the effect of Pirfenidone on NSCLC cells Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated the single drug potency of Pirfenidone, an approved drug for the treatment of lung fibrosis which is known to inhibit TGFB1 mRNA. Human A549 and H1975 lung adenocarcinoma cell lines were stimulated for 6h and 25h with 0.75 mg/ml or 1.5 mg/ml Pirfenidone or the respective volume of PBS as vehicle control. Total RNA was extracted and subjected to transcriptome analysis by microarrays.

2019-12-17 | GSE136932 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data